Pediatric Allergic March Supported by Nationwide EHR Data
A typical allergic march started with atopic dermatitis during infancy and progressed to other allergies later in life, a multi-state study found. In total, 13.4% of pediatric study participants had two or more allergic conditions based on electronic health record (EHR) information, reported David A. Hill, MD, PhD, of Children’s Hospital of Philadelphia, and coauthors. […]
FGFR Inhibitor Stakes Claim to Post-Anti-PD-1 Role in Advanced Bladder Cancer
CHICAGO — Patients with FGFR-mutated advanced urothelial cancer that progressed after anti-PD-1/L1 therapy lived significantly longer if they received the selective FGFR inhibitor erdafitinib (Balversa) instead of chemotherapy, a randomized trial showed. Median overall survival (OS) increased from 7.8 months with physician’s choice of chemotherapy to 12.1 months with the targeted agent. Progression-free survival (PFS) […]
Enzalutamide Rechallenge Yields Small PFS Boost in Metastatic Prostate Cancer
In patients with metastatic castration-resistant prostate cancer (CRPC) who have progressed on enzalutamide (Xtandi), those who continued the treatment in combination with docetaxel and prednisolone saw improved progression-free survival (PFS), the phase IIIb PRESIDE study found. Median PFS was 9.53 months with the the enzalutamide-based combination compared with 8.28 months in those treated with placebo […]